<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00208299</url>
  </required_header>
  <id_info>
    <org_study_id>CVT 5131</org_study_id>
    <nct_id>NCT00208299</nct_id>
  </id_info>
  <brief_title>ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to
      thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The
      investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist,
      the receptor responsible for coronary vasodilation, and is being studied for potential use as
      a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will
      compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible
      myocardial perfusion defects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADVANCE MPI 1 is a multi-national, double-blind, randomized, active-controlled, parallel
      group clinical trial to evaluate the safety and efficacy of regadenoson in SPECT MPI compared
      to that of the approved pharmacological stress agent, Adenoscan. Patients referred for a
      clinically indicated pharmacological stress MPI study will be eligible for enrollment. The
      trial is designed:

        -  to compare the pharmacological stress SPECT images obtained with regadenoson to those
           obtained with Adenoscan, and

        -  to compare the safety and tolerability of the two stress agents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority of regadenoson to Adenoscan for use in single photon emission computed tomography (SPECT) myocardial perfusion imaging in assessing reversible perfusion defects</measure>
    <time_frame>After radiopharmaceutical administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability comparison of regadenoson to Adenoscan</measure>
    <time_frame>Up to two weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional comparisons of images obtained with regadenoson to those obtained with Adenoscan</measure>
    <time_frame>After radiopharmaceutical administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1231</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regadenoson</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adenoscan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson</intervention_name>
    <description>0.4 mg, bolus intravenous injection</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lexiscan</other_name>
    <other_name>CVT-3146</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>0.14 mg/kg/min for 6 minutes, intravenous infusion</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Adenoscan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Referred for a clinically indicated pharmacological stress SPECT myocardial perfusion
             imaging study

        Exclusion Criteria:

          -  Any condition precluding the safe administration of Adenoscan for a SPECT myocardial
             perfusion imaging study

          -  Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method
             of birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Multiple study locations (see Central Contact); CV Therapeutics, Inc.</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.adenoscan.com</url>
    <description>Adenoscan®</description>
  </link>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>November 24, 2009</last_update_submitted>
  <last_update_submitted_qc>November 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Philip Sager, Vice President, Clinical Research</name_title>
    <organization>Gilead Sciences</organization>
  </responsible_party>
  <keyword>Lexiscan</keyword>
  <keyword>Regadenoson</keyword>
  <keyword>Adenoscan®</keyword>
  <keyword>Adenosine</keyword>
  <keyword>SPECT Myocardial Perfusion Imaging</keyword>
  <keyword>Reversible Perfusion Defect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

